Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences

Biomarkers ◽  
2009 ◽  
Vol 14 (2) ◽  
pp. 130-136 ◽  
Author(s):  
Luigi Mariani ◽  
Rosalba Miceli ◽  
Silvia Michilin ◽  
Massimo Gion
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Ca 15.3 ◽  
Serial Determination

Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancer

2011 ◽  
Vol 25 (7) ◽  
pp. 469-477 ◽  
Author(s):  
Laura Evangelista ◽  
Zora Baretta ◽  
Lorenzo Vinante ◽  
Anna Rita Cervino ◽  
Michele Gregianin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Small Population ◽  
Serial Determination ◽  
Pet Ct

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

Clinical Significance of the New Tumor Marker MCA in the follow-up of Patients with Mammary Carcinoma

1993 ◽  
Vol 8 (2) ◽  
pp. 130-132 ◽  
Author(s):  
J. Müller-Brand ◽  
H. Mäcke
Keyword(s):  
Breast Cancer ◽  
Serum Concentration ◽  
Tumor Marker ◽  
Mammary Carcinoma ◽  
Solid Phase ◽  
Clinical Status ◽  
Subsequent Increase ◽  
Degree Of Differentiation

MCA is a mucin-like carcinoma-associated antigen which has been found in all breast cancer independent of histological type and degree of differentiation. A two-step solid-phase EIA was developed and the serum concentration of MCA was measured in 176 breast cancer patiens after surgery. Using a cutoff of 11.0 U/ml the test showed a sensitivity of 77% and a specifity of 82% when compared to clinical status. The predictive value of this tumor marker was 72% for a positive diagnosis and 93% for a negative diagnosis. Based on these observations it is recommended that determination of MCA values take place 2 to 3 times in the first postoperative week in all women with surgically treated mammary carcinoma. These MCA values should then serve as reference for further determinations, which should be performed at each check-up. A subsequent increase in the MCA value should be considered as a first sign of metastasis.

3 CA 15.3 determination in the follow-up of patients with breast cancer

The Breast ◽  
1995 ◽  
Vol 4 (1) ◽  
pp. 64-65
Author(s):  
B. Seregni ◽  
E. Bombardieri ◽  
G.L. Buraggi
Keyword(s):  
Breast Cancer ◽  
Ca 15.3

Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

1995 ◽  
Vol 10 (1) ◽  
pp. 30-34 ◽  
Author(s):  
L. Vankrieken ◽  
F. Heureux ◽  
J. Longueville ◽  
R. De Hertogh
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Situation ◽  
Breast Cancer Patients ◽  
Significant Information ◽  
Ca 15.3 ◽  
Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation

1993 ◽  
Vol 39 (10) ◽  
pp. 2077-2083 ◽  
Author(s):  
G Sölétormos ◽  
V Schiøler ◽  
D Nielsen ◽  
T Skovsgaard ◽  
P Dombernowsky
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Biological Variation ◽  
Tissue Polypeptide Antigen ◽  
Ca 15.3 ◽  
Significant Difference ◽  
Initial Identification ◽  
Analytical Imprecision ◽  
Interpretation Of Results

Abstract Interpretation of results for CA 15.3, carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) during breast cancer monitoring requires data on intra- (CVP) and inter- (CVG) individual biological variation, analytical imprecision (CVA), and indices of individuality. The average CVP and CVG obtained from 22 healthy women were, respectively, 6.2% and 62.9% (CA 15.3), 9.3% and 86.8% (CEA), and 28.3% and 133% (TPA). The indices of individuality were all &lt; 0.6: 0.2 (CA 15.3), 0.15 (CEA), and 0.2 (TPA). CVA depended on the concentration of the analytes. CVP and CVA determine what constitutes a significant difference between sequential results. Assuming a CVA of 11.2% (CA 15.3), 9.5% (CEA), or 11.9% (TPA), results must differ by 30%, 31%, or 72%, respectively, for P &lt; or = 0.05. We found that CVP and CVA contribute considerably to the variation during breast cancer monitoring. Consequently, both CVP and CVA should be considered in criteria for marker evaluation. Because of low indices of individuality, conventional cutoff limits are inappropriate both for initial identification and for follow-up of breast cancer.

Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma

1995 ◽  
Vol 10 (1) ◽  
pp. 24-29 ◽  
Author(s):  
L. Rodríguez De Paterna ◽  
F. Arnaiz ◽  
J. Estenoz ◽  
B. Ortuño ◽  
E. Lanzós
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Serum Levels ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Combined Use ◽  
Malignant Breast

Serum levels of CEA, CA 15.3 and CA 27.29 were measured during the follow-up of 499 breast cancer patients. Studies included three different groups of women: 82 blood donors free of disease, 42 patients with non-malignant breast diseases and 499 breast cancer patients. After the determinaion of cut-off values, serum levels of tumor markers did not show significant elevations in benign breast diseases. On the basis of our results CA 15.3 (sensitivity = 57%; accuracy = 87%) was the most effective marker, CA 27.29 (sensitivity = 62%; accuracy = 83%) was the most sensitive and CEA (sensitivity = 45%; accuracy = 81%) was the least sensitive and effective marker. The combined use of markers was evaluated by step-wise logistic regression analysis. The regression coefficients showed that CA 15.3 (coeff. = 2.97) and CA 27.29 (coeff. = 1.46) were suitable for the detection of possible metastases during follow-up. Finally, we studied the relationship between pT, pN, pM and circulating levels of CA 15.3 and CA 27.29.

Sign in / Sign up

Export Citation Format

Share Document